Literature DB >> 15528154

Identification of new mutations of hepcidin and hemojuvelin in patients with HFE C282Y allele.

Giorgio Biasiotto1, Antonella Roetto, Filomena Daraio, Anna Polotti, Gian Mario Gerardi, Domenico Girelli, Laura Cremonesi, Paolo Arosio, Clara Camaschella.   

Abstract

HFE-hemochromatosis is the most common form of hereditary hemochromatosis. The disorder is associated with the homozygous C282Y mutation and has variable phenotype, being modulated by environmental and genetic factors. Candidate modifier genes are hemojuvelin and hepcidin, which are responsible for juvenile hemochromatosis. We used DHPLC to scan mutations in these genes in a cohort of unrelated patients with C282Y mutation. They consisted of 136 C282Y homozygous, 43 heterozygous, and 42 C282Y/H63D compound heterozygous, plus 62 controls subjects. Mutations and polymorphisms were found in 16 patients and 4 controls. Abnormally high indices of iron status were found in subjects C282Y/H63D heterozygous for the N196K hemojuvelin mutation and the -72C > T hepcidin substitution. The already described G71D mutation of hepcidin did not induce evident modification of the C282Y/H63D phenotype. The data show that heterozygous mutations of the hemojuvelin gene contribute like those of hepcidin to the phenotypic heterogeneity of hemochromatosis. However, they are rare and explain only a minor portion of the variable penetrance of the disorder.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15528154     DOI: 10.1016/j.bcmd.2004.08.002

Source DB:  PubMed          Journal:  Blood Cells Mol Dis        ISSN: 1079-9796            Impact factor:   3.039


  15 in total

Review 1.  Forging a field: the golden age of iron biology.

Authors:  Nancy C Andrews
Journal:  Blood       Date:  2008-07-15       Impact factor: 22.113

2.  The -582A>G variant of the HAMP promoter is not associated with high serum ferritin levels in normal subjects.

Authors:  Francesca Bruno; Sara Bonalumi; Clara Camaschella; Maurizio Ferrari; Laura Cremonesi
Journal:  Haematologica       Date:  2009-12-08       Impact factor: 9.941

3.  Hepcidin mutation in a beta-thalassemia major patient with persistent severe iron overload despite chelation therapy.

Authors:  Lorena Duca; Paola Delbini; Isabella Nava; Maria Domenica Cappellini; Anna Meo
Journal:  Intern Emerg Med       Date:  2009-09-12       Impact factor: 3.397

4.  Down-regulation of hepcidin in porphyria cutanea tarda.

Authors:  Richard S Ajioka; John D Phillips; Robert B Weiss; Diane M Dunn; Maria W Smit; Sean C Proll; Michael G Katze; James P Kushner
Journal:  Blood       Date:  2008-09-22       Impact factor: 22.113

5.  Gender-related variations in iron metabolism and liver diseases.

Authors:  Duygu D Harrison-Findik
Journal:  World J Hepatol       Date:  2010-08-27

Review 6.  Hemojuvelin: a supposed role in iron metabolism one year after its discovery.

Authors:  Peter Celec
Journal:  J Mol Med (Berl)       Date:  2005-05-05       Impact factor: 4.599

7.  Hereditary hemochromatosis: insights from the Hemochromatosis and Iron Overload Screening (HEIRS) Study.

Authors:  Gordon D McLaren; Victor R Gordeuk
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2009

8.  Non-HFE hemochromatosis.

Authors:  Paulo Caleb Júnior de Lima Santos; Carla Luana Dinardo; Rodolfo Delfini Cançado; Isolmar Tadeu Schettert; José Eduardo Krieger; Alexandre Costa Pereira
Journal:  Rev Bras Hematol Hemoter       Date:  2012

Review 9.  Non-HFE haemochromatosis.

Authors:  Daniel-F Wallace; V-Nathan Subramaniam
Journal:  World J Gastroenterol       Date:  2007-09-21       Impact factor: 5.742

10.  Clinical, pathological, and molecular correlates in ferroportin disease: a study of two novel mutations.

Authors:  Domenico Girelli; Ivana De Domenico; Claudia Bozzini; Natascia Campostrini; Fabiana Busti; Annalisa Castagna; Nadia Soriani; Laura Cremonesi; Maurizio Ferrari; Romano Colombari; Diane McVey Ward; Jerry Kaplan; Roberto Corrocher
Journal:  J Hepatol       Date:  2008-07-17       Impact factor: 25.083

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.